Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New England Journal of Medicine

Volumn 350, Issue 23, 2004, Pages 2335-2342

  Hurwitz, Herbert ^a,j   Fehrenbacher, Louis ^b   Novotny, William ^c   Cartwright, Thomas ^d   Hainsworth, John ^e   Heim, William ^f   Berlin, Jordan ^g   Baron, Ari ^h   Griffing, Susan ^c   Holmgren, Eric ^c   Ferrara, Napoleone ^c   Fyfe, Gwen ^c   Rogers, Beth ^c   Ross, Robert ^c   Kabbinavar, Fairooz ⁱ  

^a DUKE UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

^c GENENTECH INC   (United States)

^d Ocala Oncology   (United States)

^e Sarah Cannon Cancer Center   (United States)

^f Hematol/Oncol Assoc NE PA ^*  (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOPHLEBITIS; THROMBOSIS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 2542561964     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa032691     Document Type: Article

References (19)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
3. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
5. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
6. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FUILV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
10. CPT-11(Camptosar). Kalamazoo, Mich.: Pharmacia & Upjohn, 2002 (package insert).
11. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
12. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial cell growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
13. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
14. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003;52:568-73.
15. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152:1445-52.
16. Hurwitz H, Holden SN, Eckhardt SG, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Prog Proc Am Soc Clin Oncol 2002;21:82. abstract.
17. Oxaliplatin. (Eloxatin). New York: Sanofi-Synthelabo, 2004 (package insert).
18. Benson AB, Catalano PJ, Meropol NJ, O'Dwyer PJ, Giantonio BJ. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Prog Proc Am Soc Clin Oncol 2003;22:243. abstract.
19. Hurwitz H, Fehrenbacher L, Cartwright T, et al. A phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC: efficacy results in arm 3 (5-FU/LV/BV) and other exploratory analyses. Presented at the 94th AACR Annual Meeting, Washington, D.C., July 11-14, 2003. abstract. (Accessed on May 10, 2004, at http://wwwaacr.org/1132ag.asp.)